Article (Scientific journals)
Investigational insulin secretagogues for type 2 diabetes.
SCHEEN, André
2016In Expert Opinion on Investigational Drugs, 25 (4), p. 405-22
Peer Reviewed verified by ORBi
 

Files


Full Text
2016 EoID Investigational insulin secretagogues for type 2 diabetes.pdf
Publisher postprint (977.47 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Beta cell; GPR agonist; glucokinase activator; imeglimin; incretin; insulin secretion; type 2 diabetes
Abstract :
[en] INTRODUCTION: Insulin secretory defects are a key feature in the pathophysiology of type 2 diabetes (T2D). Classical insulin-secreting agents such as sulfonlyureas stimulate insulin secretion independent of glucose and cause hypoglycemia. Despite the advantages offered by incretin-based therapies, there is still a medical need for developing new insulin secretagogues for treating T2D. AREA COVERED: This article discusses: the new advances in the field of incretin-based therapies, glucokinase (GK) activators, free fatty acid receptor (FFAR) or G protein-coupled receptor (GPR) agonists (GPR40, GPR119, GPR120), imeglimin and some other insulin secretagogues with diverse mechanisms of action still in preclinical development. EXPERT OPINION: New insulin secretagogues should offer major advantages over sulfonylureas and gliptins. The challenge is to avoid uncontrolled insulin secretion and minimize the risk of hypoglycemia, to protect cells from progressive loss of mass and function for a better durability of glucose control, and to offer a good safety profile. Numerous approaches are in development. However, it is too early to decide whether one new pharmacological class will emerge as a clinically useful insulin secretagogue in the near feature.
Disciplines :
Endocrinology, metabolism & nutrition
Pharmacy, pharmacology & toxicology
Author, co-author :
SCHEEN, André  ;  Centre Hospitalier Universitaire de Liège - CHU > Service de diabétologie, nutrition, maladies métaboliques
Language :
English
Title :
Investigational insulin secretagogues for type 2 diabetes.
Publication date :
2016
Journal title :
Expert Opinion on Investigational Drugs
ISSN :
1354-3784
eISSN :
1744-7658
Publisher :
Taylor & Francis, United Kingdom
Volume :
25
Issue :
4
Pages :
405-22
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 07 April 2016

Statistics


Number of views
84 (3 by ULiège)
Number of downloads
1 (1 by ULiège)

Scopus citations®
 
36
Scopus citations®
without self-citations
33
OpenCitations
 
27

Bibliography


Similar publications



Contact ORBi